Sugi Predict

Sugi Predict / Compounds / SCHEMBL945487

SCHEMBL945487

SCHEMBL945487

O=c1ccccn1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ TSHR P16473 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MAPK14 Q16539 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ PKM P14618 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ AGXT P21549 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HBB P68871 1/20 0.37
▸ NR4A1 P22736 1/20 0.37
▸ NR4A2 P43354 1/20 0.37
▸ NR4A3 Q92570 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314777 0.86 MCHR1 (0.46) ALDH1A1TSHRSMN1; SMN2IDO1AGXT
SCHEMBL13933218 0.82 ALDH1A1 (0.40) ALDH1A1TSHRSMN1; SMN2MAPTKMT2A
SCHEMBL9985319 0.82 LPL (0.37) ALDH1A1TSHRMEN1MAPTKMT2A
SCHEMBL12032479 0.82 MAPT (0.35) ALDH1A1TSHRSMN1; SMN2MAPK14MEN1
SCHEMBL27716055 0.81 IDH1 (0.41) IDO1CA1CA2CA9LMNA
SCHEMBL12032410 0.80 ALDH1A1 (0.35) ALDH1A1TSHRSMN1; SMN2MEN1MAPT
SCHEMBL13918956 0.78 TACR1 (0.39) ALDH1A1TSHRSMN1; SMN2IDO1MAPT
SCHEMBL22925879 0.78 MAPK14 (0.43) ALDH1A1TSHRSMN1; SMN2MAPK14MEN1
SCHEMBL22925525 0.78 SMN1; SMN2 (0.49) ALDH1A1TSHRSMN1; SMN2MAPK14ALOX15
SCHEMBL1041560 0.76 GABRA1 (0.42) ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010834-A Piroctone derivative, and preparation method and application thereof 中国海洋大学 2026-05-12 — — CN disclosed
EP-4323342-A1 FUNGICIDAL PYRIDONES FMC CORPORATION (US) 2024-02-21 — — EP disclosed
CN-117377468-A 2, 6-dichlorophenyl ester compound and application thereof 融合制药公司 2024-01-09 — — CN disclosed
WO-2022221165-A1 FUNGICIDAL PYRIDONES FMC CORPORATION (US) 2022-10-20 — — WO disclosed
US-8889638-B2 Stimulus-triggered prodrugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-18 — — US disclosed
US-8889638-B2 Stimulus-triggered prodrugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-18 — — US disclosed
US-8889638-B2 Stimulus-triggered prodrugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-18 — — US disclosed
US-20110312905-A1 STIMULUS-TRIGGERED PRODRUGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-22 — — US disclosed
US-20110312905-A1 STIMULUS-TRIGGERED PRODRUGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-22 — — US disclosed
US-20110312905-A1 STIMULUS-TRIGGERED PRODRUGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-22 — — US disclosed
US-7875633-B2 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-25 — — US disclosed
WO-2011003007-A1 AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-06 — — WO disclosed
EP-1921065-B1 PHENYLPYRIDONE DERIVATIVE BANYU PHARMA CO LTD (JP) 2010-10-20 — — EP disclosed
EP-1666551-B1 Ink for ink jet-recording curable through irradiation and method for preparing lithographic printing plates using the same FUJIFILM CORP (JP) 2010-02-17 — — EP disclosed
US-7635181-B2 Ink for ink jet-recording curable through irradiation with a radioactive ray and method for preparing lithographic printing plates using the same FUJIFILM CORPORATION (JP) 2009-12-22 — — US disclosed
US-7635181-B2 Ink for ink jet-recording curable through irradiation with a radioactive ray and method for preparing lithographic printing plates using the same FUJIFILM CORPORATION (JP) 2009-12-22 — — US disclosed
CN-101547908-A Heterocyclic derived metalloprotease inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-09-30 — — CN disclosed
US-20090137587-A1 Phenylpyridone Derivative MSD K.K. (JP) 2009-05-28 — — US disclosed
EP-1921065-A1 PHENYLPYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137587-A1 Phenylpyridone Derivative NAT1, NPR1, PC ALDH1A1 612/4885TSHR 1390/4885SMN1; SMN2 552/4885
US-20110312905-A1 STIMULUS-TRIGGERED PRODRUGS PREP, ADAM10, DNPEP ALDH1A1 1555/4885TSHR 4291/4885SMN1; SMN2 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.